Clinical trials: Progressive Supranuclear Palsy(PSP)
Idiopathic Parkinson's Disease, Progressive Supranuclear Palsy
Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy.
The purpose of this research study is to evaluate safety and effectiveness of Foot Mechanical stimulation to improving Gait and Gait Related Disorders in Parkinson Disease and Progressive Supranuclear Palsy both stable and with…
- Trial name
- GONDOLAPILOTA (NCT01815281)
- Testing
- Foot Mechanical Stimulation (GONDOLA)
- Where
- 3 sites in Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy
Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders
Study Rationale: No accurate tests currently exist to diagnose Parkinson's disease (PD) and the conditions which mimic it (atypical parkinsonism) at a very early stage.
- Conditions
- Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration
- Trial name
- NCT05638477
- Testing
- Free-viewing eye tracking
- Where
- Ireland
- Volunteers
- 122 people
- Sponsor
- Conor Fearon
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Dementia, Alzheimer Disease
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease…
- Conditions
- Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- CRND TorCA (NCT06529744)
- Where
- 4 sites in Canada
- Volunteers
- 500 people
- Sponsor
- University Health Network, Toronto
Parkinson's Disease, Parkinsonism
VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
VISMEMO-PD is an observational pilot study aimed at investigating visuospatial memory in reaching space and topographical memory in navigational space in patients with Parkinson's disease and Parkinsonism.
- Conditions
- Parkinson's Disease, Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- VISMEMO-PD (NCT07827963)
- Testing
- Multimodal visuospatial and topographical memory assessment
- Where
- 3 sites in Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
Parkinson Disease, Multiple System Atrophy, Parkinson Variant
Automated Imaging Differentiation of Parkinsonism
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
- Trial name
- AIDP (NCT05913687)
- Testing
- AIDP
- Where
- 21 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- University of Florida
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy…
- Trial name
- NCT01348061
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- KineMed
PSP - Progressive Supranuclear Palsy
Study Evaluating the Effect of Transcranial Direct Current Stimulation (tDCS) Targeting the Right Inferior Frontal Gyrus on Inhibitory Control in Patients With PSP
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease with a prevalence estimated at 6 per 100,000 in France and a rapidly progressive course.
- Trial name
- TinPSP (NCT07818733)
- Testing
- tDCS, or transcranial direct current stimulation
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Nantes University Hospital
Alzheimer's Disease (AD), Parkinson's Disease (PD)
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
The goal of this study is to assess [18F]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease…
- Conditions
- Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT02103894
- Testing
- [18F]T807 ([18F]MNI-777)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease, Progressive Supranuclear Palsy
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Tau protein has been identified as one of the key pathological features of Tau proteinopathies, such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD).
- Conditions
- Alzheimer Disease, Progressive Supranuclear Palsy, Frontotemporal Dementia
- Trial name
- NCT05260151
- Where
- China
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Progressive Supranuclear Palsy, Corticobasal Degeneration
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)
Treatment of tauopathies such as Progressive Supranuclear Palsy (PSP) and Cortico Basal Degeneration (CBD) remains a major challenge.
- Trial name
- APOPARKA (NCT04786158)
- Testing
- Apomorphine
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Progressive Supranuclear Palsy
Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism
There is evidence suggesting that stem cells harvested from the bone marrow and transplanted into the brain may be effective in slowing down the progression of parkinsonism.
- Trial name
- NCT01824121
- Testing
- stem cell therapy
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Progressive Supranuclear Palsy, Multiple System Atrophy
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
At present, the diagnosis of Parkinsons disease(PD) mainly relies on clinical symptoms and is easily confused with atypical Parkinsonian syndrome(APS) in the early stages. There is an urgent need for reliable biomarkers.
- Conditions
- Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson's Disease
- Trial name
- NCT06490926
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA)
Neuroinflammation in FTLD
The goal of this observational study is to investigate the role of neuroinflammation in frontotemporal lobar degeneration (FTLD). The main aims of this study are: 1.
- Conditions
- Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT06870838
- Testing
- 7T MRI scan, CSF, Blood withdrawal
- Where
- 2 sites in Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Progressive Supranuclear Palsy, Healthy Volunteers
Evaluation of [18F]APN-1607 as a PET Biomarker
The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
- Trial name
- NCT05005819
- Testing
- [18F] APN-1607
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Progressive Supranuclear Palsy, Cortico Basal Degeneration
Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes
The study will compare health care utilisation and quality of life for patients with progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy in different parts of the region that our specialist clinic…
- Conditions
- Progressive Supranuclear Palsy, Cortico Basal Degeneration, Multiple System Atrophy
- Trial name
- UHSQOLAPS (NCT06645626)
- Where
- United Kingdom
- Volunteers
- 198 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Progressive Supranuclear Palsy
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy, (PSP).
- Trial name
- NCT05819658
- Testing
- GV1001 0.56mg, GV1001 1.12mg
- Where
- 5 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GemVax & Kael
PSP - Progressive Supranuclear Palsy
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
- Trial name
- NCT07217665
- Testing
- AADvac1
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Adam Boxer
Parkinson Disease, Parkinsons Disease With Dementia
A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Parkinson's Disease.
- Conditions
- Parkinson Disease, Parkinsons Disease With Dementia, Parkinson-Dementia Syndrome, Parkinson Disease 2
- Trial name
- NCT04148326
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome